Cargando…
IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma
Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcino...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980806/ https://www.ncbi.nlm.nih.gov/pubmed/29279511 http://dx.doi.org/10.2169/internalmedicine.9814-17 |
_version_ | 1783327912523464704 |
---|---|
author | Kishi, Seiji Minato, Masanori Saijo, Atsuro Murakami, Naoka Tamaki, Masanori Matsuura, Motokazu Murakami, Taichi Nagai, Kojiro Abe, Hideharu Nishioka, Yasuhiko Doi, Toshio |
author_facet | Kishi, Seiji Minato, Masanori Saijo, Atsuro Murakami, Naoka Tamaki, Masanori Matsuura, Motokazu Murakami, Taichi Nagai, Kojiro Abe, Hideharu Nishioka, Yasuhiko Doi, Toshio |
author_sort | Kishi, Seiji |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury. |
format | Online Article Text |
id | pubmed-5980806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-59808062018-06-04 IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma Kishi, Seiji Minato, Masanori Saijo, Atsuro Murakami, Naoka Tamaki, Masanori Matsuura, Motokazu Murakami, Taichi Nagai, Kojiro Abe, Hideharu Nishioka, Yasuhiko Doi, Toshio Intern Med Case Report Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury. The Japanese Society of Internal Medicine 2017-12-27 2018-05-01 /pmc/articles/PMC5980806/ /pubmed/29279511 http://dx.doi.org/10.2169/internalmedicine.9814-17 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Kishi, Seiji Minato, Masanori Saijo, Atsuro Murakami, Naoka Tamaki, Masanori Matsuura, Motokazu Murakami, Taichi Nagai, Kojiro Abe, Hideharu Nishioka, Yasuhiko Doi, Toshio IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title | IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title_full | IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title_fullStr | IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title_full_unstemmed | IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title_short | IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma |
title_sort | iga nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980806/ https://www.ncbi.nlm.nih.gov/pubmed/29279511 http://dx.doi.org/10.2169/internalmedicine.9814-17 |
work_keys_str_mv | AT kishiseiji iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT minatomasanori iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT saijoatsuro iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT murakaminaoka iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT tamakimasanori iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT matsuuramotokazu iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT murakamitaichi iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT nagaikojiro iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT abehideharu iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT nishiokayasuhiko iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma AT doitoshio iganephropathyafternivolumabtherapyforpostoperativerecurrenceoflungsquamouscellcarcinoma |